Jackson Park Capital LLC maintained its stake in Kindred Biosciences Inc. (NASDAQ:KIN) during the second quarter, Holdings Channel reports. The firm owned 77,000 shares of the biopharmaceutical company’s stock at the end of the second quarter. Jackson Park Capital LLC’s holdings in Kindred Biosciences were worth $273,000 as of its most recent filing with the SEC.
Separately, BlackRock Institutional Trust Company N.A. raised its stake in Kindred Biosciences by 205.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 68,285 shares of the biopharmaceutical company’s stock valued at $236,000 after buying an additional 45,930 shares in the last quarter. 64.38% of the stock is owned by institutional investors and hedge funds.
Shares of Kindred Biosciences Inc. (NASDAQ:KIN) traded down 2.62% on Friday, hitting $4.84. The stock had a trading volume of 22,401 shares. Kindred Biosciences Inc. has a 12 month low of $2.90 and a 12 month high of $6.38. The stock’s market cap is $96.27 million. The firm has a 50 day moving average of $4.67 and a 200 day moving average of $3.96.
Kindred Biosciences (NASDAQ:KIN) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.07. On average, equities analysts forecast that Kindred Biosciences Inc. will post ($1.22) earnings per share for the current fiscal year.
Separately, Zacks Investment Research upgraded Kindred Biosciences from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Monday, September 5th.
Kindred Biosciences Company Profile
Kindred Biosciences, Inc is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products.
Want to see what other hedge funds are holding KIN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kindred Biosciences Inc. (NASDAQ:KIN).
Receive News & Ratings for Kindred Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.